Personalized Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcoma Patients A Study of Surgery and Chemotherapy Effects on Tumor Biology and Outcomes

What this Trial Is About

Researchers are investigating a personalized approach to neoadjuvant chemotherapy NCT for patients with high-risk soft tissue sarcoma STS, including subtypes such as dedifferentiated liposarcoma, leiomyosarcoma, synovial sarcoma, vascular sarcomas, and malignant peripheral nerve sheath tumor. This study includes both retrospective and prospective collection of tissue samples from patients either undergoing surgery alone or receiving NCT followed by surgery. The goal is to better understand the biology of these cancers and improve treatment strategies through precision medicine. The study takes place across multiple centers in four countries and involves two main patient groups those who proceed directly to surgery control group and those who receive NCT before surgery. Tissue samples and clinical data will be collected before chemotherapy and after surgery to analyze genomic, proteomic, and epigenetic changes. The project also includes retrospective data and tissue collection from similar patient groups to expand the analysis. Data and tissue transfers comply with regulatory and confidentiality standards. Participants will provide consent and undergo tissue sampling, with clinical information pseudonymized for privacy. Researchers will evaluate differences in expression profiles, radiomic data, and develop a tissue atlas, patient-derived models, and a nomogram app to predict treatment benefits and recurrence risks over an average of four years. Outcomes measured include metastases-free survival, recurrence-free survival, and overall survival. The study aims to enhance personalized treatment options for high-risk sarcoma patients.

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients